NCT03420014 - Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Leiomyosarcoma

Interventions

DRUG

Doxorubicin

75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).

COMBINATION_PRODUCT

L19TNF plus doxorubicin

13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.

Trial Locations (8)

32224

RECRUITING

Mayo Clinic Hospital, Jacksonville

43202

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

55905

RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University, St Louis

85054

RECRUITING

Mayo Clinic Hospital, Phoenix

90403

RECRUITING

Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California, Santa Monica

98109

RECRUITING

Seattle Cancer Care Alliance 825 Eastlake Ave. E. Seattle, WA 98109 Mail Stop CE2-128, Seattle

08901

RECRUITING

Rutgers Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08901 Room 2031, New Brunswick

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY